Overview

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Status:
Completed
Trial end date:
2014-05-09
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy and safety of etelcalcetide (AMG 416) compared with placebo in the treatment of SHPT in CKD patients receiving hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen